Jeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.
Jeannie Chern, MD, a gynecologic oncologist at Moffitt Cancer Center, discusses challenges with germline molecular testing for patients with ovarian cancer.
The cost associated with germline testing can be prohibitive for patients with ovarian cancer who are undergoing chemotherapy treatment, says Chern. However, some pharmaceutical companies may offer financial assistance so patients can be tested, explains Chern.
A lack of genetic counselors is also a rate-limiting challenge in this space, says Chern. Patients who undergo germline testing should have access to genetic counselors to help them understand whether they harbor an actionable target. Genetic counselors can also offer support and additional resources to a patient who may have a germline mutation, concludes Chern.